文献速递浆细胞疾病

多发性骨髓瘤中消除对序贯确认缓解的需求

Eliminating the need for sequential confirmation of response in multiple myeloma.
PubMed 文献 · Blood · 2025-01-01

研究回顾性分析梅奥诊所临床试验中583例确认进展事件,评估若两个疾病负荷标志物同时满足进展标准,是否仍需序贯确认;结果显示同时标准敏感性近70%,特异性98%,作者认为此时序贯评估可能并非必要。

要点

  • 583例确认进展中,近70%在首次检测时即有两个标志物同时满足进展标准。
  • 413例同时满足进展标准者中,98%后续经序贯值确认进展。
  • 作者认为两个标志物同时满足进展标准时,序贯确认可能并非必要。

核心结论

  • 对于两个疾病负荷标志物同时满足进展标准的多发性骨髓瘤患者,序贯评估任一标志物以确认进展可能并非必要。

研究设计与样本

  • 回顾性研究梅奥诊所临床试验中所有连续入组的多发性骨髓瘤患者,共识别583例确认进展事件。

主要发现

  • 583例进展事件中,近70%(同时标准的敏感性)在首次检测时即有两个标志物同时满足进展标准。
  • 413例通过两个同时值满足进展标准的患者中,98%(同时标准的特异性)后续经序贯值确认进展。

关键数值与推荐

  • 国际骨髓瘤工作组共识缓解标准目前要求任何1个标志物的2次序贯评估,在确认疾病进展和启动新治疗前进行。
  • 同时标准敏感性近70%,特异性98%。

临床怎么用

  • 作者认为,对于两个疾病负荷标志物同时满足进展标准的患者,序贯评估任一标志物以确认进展可能并非必要。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Disease response and progression assessment in multiple myeloma is based on various measurements of monoclonal protein (serum and urine protein electrophoresis, serum free light chain, and/or quantitative immunoglobulins). Currently, the International Myeloma Working Group consensus response criteria require 2 sequential assessments of any 1 marker made at any time before confirmation of disease progression and the institution of any new therapy. However, this can be cumbersome in clinical trials. Herein, we hypothesized that if 2 markers meet the progression criteria simultaneously, a repeat of either will not be necessary for confirmation. We retrospectively studied all sequential patients with myeloma enrolled in clinical trials at Mayo Clinic. We identified 583 episodes of confirmed progression in our study. Among the 583 progression episodes, nearly 70% (sensitivity of the simultaneous criteria) met the 2 simultaneous variable criteria at the first testing, indicating progression. Conversely, among 413 patients who met progression criteria by 2 simultaneous values, 98% (specificity of the simultaneous criteria) of patients subsequently had confirmed progression by sequential values. In summary, for patients with 2 disease burden markers meeting the simultaneous progression criteria, sequential assessment of either 1 for confirmation may not be necessary to determine disease progression.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Claveau JS, Kapoor P, Binder M, et al. Eliminating the need for sequential confirmation of response in multiple myeloma. Blood. 2025. PMID: 40489635. doi:10.1182/blood.2024027949

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。